[Note: The full text of this open-access article is available free online at http://rheumatology.oxfordjournals.org/cgi/reprint/47/5/665
Objectives: Dose-dependant gastrointestinal and cardiovascular side-effects limit the use of NSAIDs [non-steroidal anti-inflammatory drugs such as aspirin, ibuprofen, and indomethacin] in the management of RA [rheumatoid arthritis – a chronic autoimmune inflammatory joint disease in which inflammation plays a key role]. The n-3 [omega-3] essential fatty acids (EFAs) have previously demonstrated some anti-inflammatory and NSAID-sparing properties. The objective of this study was to determine whether cod liver oil supplementation helps reduce daily NSAID requirement of patients with RA.
Methods: Dual-centre, double-blind placebo-controlled randomized study of 9 months' duration. Ninety-seven patients with RA were randomized to take either 10 g of cod liver oil containing 2.2 g of n-3 EFAs or air-filled identical placebo capsules. Documentation of NSAID daily requirement, clinical and laboratory parameters of RA disease activity and safety checks were done at 0, 4, 12, 24 and 36 weeks.
At 12 weeks, patients were instructed to gradually reduce, and if possible, stop their NSAID intake. Relative reduction of daily NSAID requirement by >30% after 9 months was the primary outcome measure.
Results: Fifty-eight patients (60%) completed the study. Out of 49 patients, 19 (39%) in the cod liver oil group; and out of 48 patients, 5 (10%) in the placebo group were able to reduce their daily NSAID requirement by >30% (P = 0.002, chi-squared test).
No differences between the groups were observed in the clinical parameters of RA disease activity or in the side-effects observed.
Conclusions: This study suggests that cod liver oil supplements containing omega-3 fatty acids can be used as NSAID-sparing agents in RA patients.
Source: Rheumatology (Oxford), May 2008;47(5):665-9. PMID: 18362100, by Galarraga B, Ho M, Youssef HM, Hill A, McMahon H, Hall C, Ogston S, Nuki G, Belch JJ. Vascular and Inflammatory Diseases Research Unit, University Division of Medicine and Therapeutics, Ninewells Hospital and Medical School, Dundee, UK. [E-mail: firstname.lastname@example.org]